The Interactions between Sleep Disordered Breathing, Metabolic Syndrome and Vascular Risk.

睡眠呼吸障碍、代谢综合征和血管风险之间的相互作用。

• 批准号: nhmrc : 310300
• 负责人: Dr Christopher Worsnop
• 金额: $ 24.07万
• 依托单位: Institute for Breathing and Sleep
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/interactions-sleep-disordered-vascular-risk/97520
• 关键词: Interactions; between; Sleep; Disordered; Breathing

We will look at two common diseases in the Australian community, the metabolic syndrome and obstructive sleep apnoea (OSA), and explore the common links they have to the risk of disease of the heart and blood vessels. We will then take a group of patients who have both diseases, treat the OSA, and assess the impact of this treatment on their cardiovascular health. Metabolic syndrome is a term given to patients who have high blood sugar, obesity, high lipid levels and raised blood pressure. The Australian Bureau of Statistics estimates that half the Australian population is overweight, and US studies suggest that nearly of the adult population has metabolic syndrome. This is strongly linked to diseases of the heart and blood vessels, eg heart attacks and stroke. Patients with OSA stop breathing during the night when their throat closes over. The blood oxygen falls, which causes the patient to wake momentarily, then start breathing again. This cycle repeats itself throughout the night. The usual treatment is an air pump (CPAP) connected to a nose mask, which blows air into the throat and prevents closure. This disease is strongly linked to high blood pressure, raised blood sugar levels and heart and blood vessel disease. Patients with the metabolic syndrome will have an overnight sleep study to diagnose OSA, giving the likelihood of having OSA in this group of patients. They will then have extensive investigations of the health of their heart and blood vessels. From these, we will determine which aspects of OSA are more likely to result in cardiovascular disease. Those patients diagnosed with OSA will be treated with CPAP for 3 months. Half the patients will receive normal CPAP; the other half will receive ineffective CPAP. They will then be re-tested and we will compare the results before and after treatment. Thus we will measure likelihood of OSA in this large group of patients, and the health benefits they may gain from treatment of their OSA.

我们将研究澳大利亚社区的两种常见疾病，代谢综合征和阻塞性睡眠呼吸暂停（OSA），并探讨它们与心脏和血管疾病风险的共同联系。然后，我们将采取一组同时患有这两种疾病的患者，治疗OSA，并评估这种治疗对他们心血管健康的影响。代谢综合征是一个术语，指的是患有高血糖、肥胖、高血脂和高血压的患者。澳大利亚统计局估计，澳大利亚一半的人口超重，美国的研究表明，近一半的成年人患有代谢综合征。这与心脏和血管疾病密切相关，例如心脏病发作和中风。阻塞性睡眠呼吸暂停症患者在夜间喉咙闭合时停止呼吸。血氧福尔斯下降，导致患者短暂醒来，然后再次开始呼吸。这个循环在整个晚上重复。通常的治疗方法是将空气泵（CPAP）连接到鼻罩上，将空气吹入喉咙并防止关闭。这种疾病与高血压、血糖水平升高以及心脏和血管疾病密切相关。患有代谢综合征的患者将进行过夜睡眠研究以诊断OSA，从而确定这组患者患有OSA的可能性。然后，他们将对他们的心脏和血管的健康状况进行广泛的调查。从这些，我们将确定OSA的哪些方面更容易导致心血管疾病。诊断为OSA的患者将接受CPAP治疗3个月。一半的患者将接受正常的CPAP;另一半将接受无效的CPAP。然后，他们将重新测试，我们将比较治疗前后的结果。因此，我们将测量这一大群患者中OSA的可能性，以及他们从OSA治疗中可能获得的健康益处。